Connect with us

Business

Shipping delays impact Pfizer vaccine supply in KFL&A – Kingston News – Kingstonist

Published

 on


Nursing staff at Kingston Health Sciences Centre administer the first dose of the Pfizer-BioNTech COVID-19 vaccine in southeastern Ontario to Nanette Isaac, from Extendicare as part of the province-wide vaccination campaign, at the COVID-19 Vaccination Clinic at Kingston, Ontario, Canada. (Photo by Matthew Manor/KHSC)

KFL&A Public Health says it has been notified by the Ministry of Health of a shipment delay impacting the delivery of Pfizer vaccine to the Kingston, Frontenac, Lennox and Addington region.

“In response to this unexpected delay,” KFL&A Public Health says, “most clinics in the KFL&A region will move to offer Moderna vaccine with a limited supply of Pfizer vaccine available for individuals who are 18 to 29 years old where there is a provincial recommendation to receive Pfizer due to a potential increased risk for pericarditis or myocarditis.”

The local Public Health Unit says there is adequate supply of Moderna vaccine for adult third doses, and vaccination clinics will continue to run at full capacity. “Please note individuals 30 years of age and older may be offered Moderna vaccine as their third dose until additional vaccine supply is received,” KFL&A Public Health says.

According to the Public Health Unit, the Paediatric Pfizer vaccine dose for 5 to 11 years of age is still available and will continue to be offered at the clinics for this age group.

“I urge all residents to access their third dose in any approved combination as quickly as possible to protect themselves, their loved ones, and our community,” says Dr. Piotr Oglaza, Medical Officer of Health at KFL&A Public Health. “Mixing doses is not a new practice – the National Advisory Committee on Immunization (NACI), the Canadian agency that oversees all vaccines and their use, state that the mixing of COVID-19 vaccine is safe and effective.”

“We want to remind our residents that both Moderna and Pfizer vaccines are approved by Health Canada and use a similar mRNA technology, so the vaccines are interchangeable and safe to mix,” KFL&A Public Health advises.

According to KFL&A Public Health, vaccination clinics will continue to run at full capacity in the KFL&A region. Booking can be done through KFL&A Public Health’s online vaccine clinic tool. KFL&A Public Health encourages residents to get their third dose of COVID-19 vaccine (when eligible) in any approved combination to achieve maximum protection against the highly transmissible Omicron variant in our region.

Adblock test (Why?)



Source link

Continue Reading

Business

Health Canada approves Pfizer's COVID-19 therapeutic – CBC News

Published

 on


Health Canada has approved Pfizer’s COVID-19 therapeutic for use in adults 18 and older, paving the way for the distribution of a potentially lifesaving drug at a time when the country’s hospitals are overwhelmed.

Pfizer’s Paxlovid, an oral antiviral prescribed by a doctor and administered in pill form, is designed to help the body fight off the SARS-CoV-2 virus, reduce symptoms from an infection and shorten the period of illness.

After months of clinical trials, Pfizer reported in November that Paxlovid reduced the risk of hospitalization or death by an impressive 89 per cent compared to a placebo in non-hospitalized high-risk adults with COVID-19.

The drug company’s laboratory studies also indicate the drug is likely to work against the Omicron variant, now the dominant variant among new cases in Canada.

The product has been hailed as a pandemic “game changer” by some doctors because it could reduce hospitalizations and deaths among COVID-19 patients.

Experts say an effective pill that’s easy to self-administer at home could relieve some of the pressure on the health care system and change the trajectory of the pandemic. Existing therapeutics approved for use in Canada — products like monoclonal antibodies and remdesivir — must be administered intravenously in a hospital setting.

WATCH: Health Canada approves Pfizer’s oral COVID treatment

Health Canada approves Pfizer’s oral COVID treatment

6 hours ago

Duration 1:29

Dr. Supriya Sharma, chief medical adviser to the deputy minister of health, announces Canada’s approval of a new prescription COVID treatment. 1:29

Speaking at a press conference with reporters Monday, Dr. Theresa Tam, Canada’s chief public health officer, said the regulator’s approval is “great news” because Paxlovid could drive down severe outcomes in the current wave and beyond.

“The regulator as well as the experts helping us with the guidance and the supply are all coming together at once and I think Canadians should be very happy today to hear that oral antivirals are beginning to become available in Canada,” she said.

Canada has placed an order for an initial quantity of one million treatment courses, with an option to buy up to 500,000 more. With global interest in antivirals running high as the Omicron variant wreaks havoc, Pfizer is promising to churn out 120 million courses of the treatment by year’s end.

Health Minister Jean-Yves Duclos said 30,000 treatment courses have arrived in Canada already and will be distributed to the provinces and territories on a per-capita basis.

Duclos said another 120,000 Paxlovid treatments will arrive between now and the end of March. The federal government is working with Pfizer to bring “additional treatment courses to Canada as quickly as possible,” he said.

WATCH: Health minister says Canada should have 150,000 Paxlovid treatments by March 

Health minister says Canada should have 150,000 Paxlovid treatments by March

4 hours ago

Duration 1:02

Health Minister Jean-Yves Duclos says over 120,000 Paxlovid treatments are expected by March, in addition to the 30,000 already distributed. 1:02

While championing Paxlovid as a treatment that will “save lives, reduce illness and lighten the load on our health care system,” Duclos said this antiviral is not a replacement for vaccines, which remain the best way to keep people out of hospital. 

“This is welcome news — we have one more tool in our toolbox. But no drug, including Paxlovid, can replace vaccination and public health measures,” he said. “You don’t want to have to use that pill if you can instead be vaccinated. Vaccination will be a lot better in protecting you.”

Tam said the Public Health Agency of Canada (PHAC) is working with its provincial and territorial counterparts to determine how best to distribute antivirals, which are expected to be in short supply for the foreseeable future.

“This treatment, the first treatment taken orally and at home, will be in high demand,” she said. “We anticipate supply at the beginning will not be great anywhere.”

The product, which doesn’t prevent infection, has been authorized by Health Canada for use in high-risk adults with mild or moderate COVID-19 symptoms.

A spokesperson for Ontario’s Health Minister Christine Elliott said the country’s largest province will earmark its share — about 10,000 courses of treatment to start — for adults with “the highest risk of severe outcomes, including immunocompromised patients.”

A person should start taking Paxlovid no more than five days after symptoms start, which could be “one of the key challenges of these antivirals,” Tam said.

‘An important tool’

“They have to be given really early. Not easy, but everybody needs to give it a good try because it could be an important tool going forward,” she said. “It could potentially blunt the severity of the virus, which is a a key goal.”

Health Canada said Pfizer’s pills should only be used by patients who have tested positive on a SARS-CoV-2 viral test. Such tests are currently in short supply in some provinces and territories.

If a PCR test is not available, Tam said a positive result on a rapid antigen test would also suffice.

In a statement, Conservative MP Luc Bethold, the party’s health critic, urged the federal government to “rectify the lack of available testing” plaguing many provinces so these therapeutics can be deployed quickly.

Dr. Isaac Bogoch, an infectious disease specialist and researcher based at Toronto General Hospital, said Health Canada’s approval is “a very positive first step.”

“Everything we’ve heard about this pill is very promising but there are clearly logistical challenges ahead,” he said, adding that careful planning is required to make sure the pills get to those who need them most.

This drug regimen could be useful for people who have underlying conditions that increase the risk of hospitalization and death related to the coronavirus, such as heart disease or diabetes.

It could also be given to the unvaccinated, who are much more likely to experience severe outcomes. Tam pointed to PHAC data that suggest unvaccinated people are 19 times more likely to be hospitalized with COVID-19 than fully vaccinated people.

Health Canada has warned, however, that the product shouldn’t be used while a patient is on any of a long list of other drugs, including common medications used to treat erectile dysfunction, high cholesterol and seasonal allergies, among others.

“If you’re on certain medications, you have to be careful when using this drug,” Tam said, urging prescribers to review contraindications before writing a script for Paxlovid. 

Pfizer’s treatment is meant to be taken as 30 pills over five days. Patients take three pills at a time: two of Pfizer’s pills and one of a low-dose HIV drug known as ritonavir, which helps Pfizer’s drug remain active in the body longer.

Adblock test (Why?)



Source link

Continue Reading

Business

Workers at Teck Resources’ British Columbia mine to hold ratification vote

Published

 on

Canadian miner Teck Resources Ltd said on Monday that a union representing 1,048 workers at its British Columbia mine has agreed to hold a ratification vote on the mediators’ recommendation.

The union will schedule a ratification vote to be concluded no later than January 24, the company said.

Last week, the company said it had received a strike notice https://reut.rs/3A7TJZQ from the union at its Highland Valley Copper Operations in British Columbia, without providing any reasons behind the potential strike.

 

(Reporting by Rithika Krishna in Bengaluru; Editing by Chizu Nomiyama)

Continue Reading

Business

Markets split on BoC decision as business survey, inflation loom – BNN

Published

 on


Columnist image

The Bank of Canada is getting a pair of key indicators this week ahead of a rate decision next Wednesday that’s virtually a coin toss, as far as markets are concerned.

First up on Monday, the central bank releases its quarterly Business Outlook Survey, which provides a snapshot of how approximately 100 corporate leaders are feeling about the economy and their own business fundamentals.

When the last survey was released in October, it showed the broadest gauge of sentiment was at the highest level in the survey’s history. That was despite worsening labour shortages and as more than half of respondents (57 per cent) said they expected labour costs to accelerate over the next year.

“[Monday’s] Business Outlook Survey might have been completed too early to catch Omicron uncertainties, so expect respondents to retain a healthy dose of optimism,” said CIBC World Markets Chief Economist Avery Shenfeld in a report to clients Friday.

“The survey could show a majority expecting inflation to run above the top end of the Bank of Canada’s one-three per cent inflation band. If not for Omicron, that would spell a rate hike in January, but the uncertainties surrounding how long this disruption will last should be enough to defer that decision.”

Meanwhile, Statistics Canada will release the consumer price index for December on Wednesday. Economists are expecting to see inflation rose 4.8 per cent year-over-year in the month; that would be the fastest rate of growth since 1991.

As of 8:30 a.m. Monday morning, market data shows investors see a 59 per cent chance of a rate hike when the Bank of Canada delivers its decision on Jan. 26.

Adblock test (Why?)



Source link

Continue Reading

Trending